Johnson & Johnson has announced that its Janssen Pharmaceutica Products, L.P. unit has received a subpoena from the U.S. Office of Personnel Management, Office of the Inspector General, requesting documents related to its psychiatric medication Risperdal, prescribed to treat schizophrenia and bipolar mania.
The company is cooperating in responding to the subpoena. The company is a subsidiary of Johnson & Johnson.
Risperdal is one of the world's most widely prescribed antipsychotic drugs with a worldwide sales of $2.5 billion in 2003 -- $1.4 billion of that from the United States.
The OIG's office in the Office of Personnel Management investigates allegations of fraud and abuse within federal employee health benefits programs. No one at the office could be reached for comment Monday.